Assess the safety, tolerability and pharmacokinetics of AZD5055 following single and multiple ascending doses in healthy participants

Trial Identifier:	D8960C00001
Sponsor:	AstraZeneca
NCTID::	NCT05134727
Start Date:	November 2021
Primary Completion Date:	March 2023
Study Completion Date:	March 2023
Condition:	Pulmonary Fibrosis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, MD	Brooklyn, MD, US, 21225

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.